Conference abstractPublished 15 Nov 2018

Co-administration of cerebrolysin and 5-HT6 receptor antagonist induced superior neuroprotection following exacerbation of brain pathology in sleep deprivation by concussive head injury

Authors: Aruna Sharma, Dafin F Muresanu, Jose Vicente Lafuente, Z Ryan Tian, Asya Ozikzilcik, Hari S Sharma

Uppsala University, Sweden; Iuliu Hatieganu University of Medicine and Pharmacy, Romania; University of the Basque Country, Spain; University of Arkansas, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Sleep deprivation (SD) in military often leads to decline in cognitive and higher mental functions. Since military personnel are vulnerable to concussive head injury (CHI), it appears that SD may worsen brain pathology in CHI. Previously, we showed that 48 or 72 h SD alters serotonin (5-hydroxytryptamine, 5-HT) metabolism and induces brain pathology that is significantly reduced by 5-HT3 receptor antagonist ondansetron. Recent reports suggest that treatment with 5-HT6 receptor antagonists has also beneficial effects in attenuating behavioral and cognitive functions in brain injury. We found that cerebrolysin, a balanced composition of several neurotrophic factors and active peptide fragments when delivered through TiO2-nanowiredtechnology results in superior neuroprotective effects on brain pathology in CHI. Thus, we examined whether CHI brain pathology that is aggravated in SD could be reduced by nanodelivery of 5-HT6 receptor antagonist SB-399885 together with cerebrolysin probably having a synergistic enhanced therapeutic effects. Male Wistar rats (age 20 to 25 weeks) were subjected to 72 h SD using an inverted flowerpot model placed in a pool of water maintained at 1 cm below the surface so that animals are deprived of restful sleep. After 72 h of CHI in these animals were inflicted by dropping a weight of 114.6 g from a 20 cm height guide tube inducing and impact injury of 0.224 N on the right skull. Our observation shows that CHI in SD rats resulted in marked exacerbation of brain pathology (2 to 3 fold higher) after 4 weeks of survival. In the brain, neuronal damages in cortex, hippocampus and cerebellum, blood-brain barrier (BBB) breakdown and edema formation was also aggravated by 2-3 fold in SD rats after CHI. These SD rats after CHI also showed much worse behavioral performances on Rota-Rod treadmill, inclined plane angle test, and water maze apparatus. TiO2-nanowired delivery of 5-HT6 receptor antagonist SB-399885 (3 mg/kg) together with cerebrolysin (2.5 ml/kg) intravenously once daily for 2 weeks starting from 1 week after CHI in SD rats induced marked neuroprotection as compared to these drugs either given alone or without nanotechnology under identical conditions. Interestingly, nanowired delivery of drugs in combination also improved behavioral function remarkably in SD rats after CHI. These observations are the first to show that a combination of 5-HT6 receptor antagonist with cerebrolysin using nanodelivery has superior neuroprotective effects in CHI induced brain pathology in SD, not reported earlier.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Aruna Sharma”
  • BylineArticles whose byline prints “Dafin F Muresanu”
  • BylineArticles whose byline prints “Jose Vicente Lafuente”
  • BylineArticles whose byline prints “Z Ryan Tian”
  • BylineArticles whose byline prints “Asya Ozikzilcik”
  • BylineArticles whose byline prints “Hari S Sharma”